We are thrilled to exhibit at the 11th CAR-TCR Summit September 15th–17th in Boston, MA. This event is dedicated to advancing CAR and TCR cell therapies, providing a premier platform for scientific exchange and showcase of the latest innovations. Visit our experts at booth #44 to learn how Biocytogen’s fully human antibody discovery platforms and humanized mouse models can support the development and preclinical evaluation of next-generation cell therapies.
What is the 11th CAR-TCR Summit?
The CAR-TCR Summit is an annual conference that supports the development and translation of CAR and TCR cell therapies. Now in its 11th year, the event features more than 75 speakers to highlight emerging research and share unpublished clinical data. Attendees can participate in technical presentations, panel discussions, bootcamps, and poster sessions, as well as networking activities including 1:1 partnering meetings and the CAR-TCR Connect reception.
Event Overview
Date: September 23rd - 26th, 2026
Venue: The Westin Boston Seaport District, 425 Summer St, Boston, MA 02210
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
